Pharmaceutical

FDA approves Accord BioPharma’s HERCESSI for cancer treatment

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of HER2-overexpressing cancers.

Sep 20, 2024 - 04:00
FDA approves Accord BioPharma’s HERCESSI for cancer treatment
Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of HER2-overexpressing cancers.
Read the original article

Tags:

Previous Article

Lupin and Takeda to commercialise Vonoprazan in India

Next Article

Top three trends in precision medicine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Innate Pharma and Takeda sign licence deal to develop ADCs for coeliac disease

Innate Pharma and Takeda sign licence deal to develop A...

Apr 3, 2023

EC approves Pfizer’s Talzenna combo for prostate cancer treatment

EC approves Pfizer’s Talzenna combo for prostate cancer...

Jan 9, 2024

Scottish company secures £4.2m to advance 3D-printed micro-tumour tech

Scottish company secures £4.2m to advance 3D-printed mi...

Feb 2, 2024